It is still in the early trial stages, but participants have lost up to 13.1% of their weight in 12 weeks, compared to the 6% weight loss in 12 weeks during Wegovys early trials
These include brief stinging during injection lasting seconds to a minute, small drop of blood at the injection site, temporary redness in a quarter-sized area around the site, slight firmness or bump at the injection location, mild warmth at the site for several hours, and faint bruising that appears over the following day
Because the trial's primary and secondary endpoints were assessed at 24 and 48 weeks, published week-4 data are limited
If you want first class service, I highly recommend reaching out to her and her staff
(2021) "Once-weekly semaglutide in adults with overweight or obesity" The New England Journal of Medicine, 384(11) This article was reviewed and approved by Lujain Alhassan, Bariatric Nutritionist, on 31 October 2025
And that brings us into how many other conditions
.jpg)
